LGT Capital Partners’s Autolus Therapeutics AUTL Stock Holding History

LGT Capital Partners’s Portfolio AUTL Stock Details AUTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-370,000	Closed	-$1.29M	–	52
2024 Q2	$1.29M	Sell	370,000 -180,000	-33%	-$777K	0.04%	56
2024 Q1	$3.51M	Hold	550,000	–	–	0.11%	55
2023 Q4	$3.54M	Hold	550,000	–	–	0.11%	58
2023 Q3	$1.28M	Hold	550,000	–	–	0.05%	62
2023 Q2	$1.31M	Hold	550,000	–	–	0.05%	63
2023 Q1	$1.01M	Hold	550,000	–	–	0.03%	63
2022 Q4	$1.04M	Hold	550,000	–	–	0.03%	60
2022 Q3	$1.18M	Hold	550,000	–	–	0.04%	65
2022 Q2	$1.56M	Buy	550,000 +50,000	+10%	+$152K	0.05%	62
2022 Q1	$2.08M	Buy	+500,000	New	+$2.1M	0.06%	65

Other funds holding AUTL

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return

Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

TAM

TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

LGT Capital Partners's AUTL Position: Q3 2024 in Review

LGT Capital Partners sold out of Autolus Therapeutics (AUTL) in Q3 2024, closing a stake of 370,000 shares — an estimated $1.29M sold.

LGT Capital Partners first reported a position in AUTL in Q1 2022 and held it in 10 quarters. The position peaked at $3.54M in Q4 2023. 101 funds tracked by Wall St. Rank hold AUTL as of Q3 2024.

LGT Capital Partners reported no remaining Autolus Therapeutics position as of Q3 2024 after selling out during the quarter.
LGT Capital Partners sold 370,000 Autolus Therapeutics shares in Q3 2024, an estimated $1.29M.
LGT Capital Partners first reported a position in Autolus Therapeutics in Q1 2022 and held it in 10 quarters.
LGT Capital Partners's Autolus Therapeutics position peaked at $3.54M in Q4 2023.
101 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q3 2024.

Based on LGT Capital Partners's 13F filing for Q3 2024, filed 8 Nov 2024.